Ediphor completes its independent clinical trial for its novel Flu test with 99.3% accuracy.
Ediphor, a novel Point-Of-Care and personal digital diagnostics company, is pleased to announce the completion of an independent clinical trial for its novel Flu test.
Ediphor’s second-generation Flu test exhibited 100% specificity and 98.4% sensitivity in an independent clinical trial of 800 samples (300 positive and 500 negative). The results were compared against lateral flow and PCR flu tests.
The clinical trial was conducted by the Medical University of Gdańsk, a highly regarded academic and research institution in Poland, renowned for its extensive experience in medical research, clinical trials and performance evaluations.
This milestone result for the Company is further validation of the Ediphor diagnostic platform.
The Company is targeting a commercial launch in January 2025.